 Tonix Pharmaceuticals Holding Corp NASDAQ: TNXP announced that it received the official written response from a Type B pre-Investigational New Drug IND meeting with the FDA for its COVID-19 vaccine candidate. Based on the response, the Company expects to begin a Phase 1 study in 1H of 2022. 